BMRN · Biomarin Pharmaceutical Inc
United States · RS rating 51 · As of 2026-11-03
| Price | 55.66 USD |
|---|---|
| 1-day change | -3.1% |
| RS rating (overall / 1M / 3M / 12M) | 51 / 48 / 51 / 55 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 32 / 33 / 21 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -50.0% |
| Sales growth Q/Q | +12.7% |
| Distance from 52-week high | +20.8% |
| Market cap (USD) | $10.4B |